Max Robotics — Global Service Robot Directory + US Certification

About

Najeeb Mohideen is a radiation oncologist whose research has made significant contributions to the treatment of prostate cancer, with a particular focus on stereotactic body radiation therapy (SBRT) as a precise and effective modality for localized disease. His work centers on the clinical application of extreme hypofractionation, leveraging the favorable radiobiology of prostate cancer to deliver high doses of radiation in fewer treatment sessions — an approach with profound implications for patient convenience and healthcare efficiency. Mohideen's most impactful contribution is his leadership in multicenter clinical trials evaluating SBRT for low- and intermediate-risk prostate cancer. His 2018 paper, garnering 128 citations, demonstrated that dose-escalated SBRT could be safely administered across multiple institutions, establishing critical evidence for the approach's reproducibility and safety at scale. Earlier work from 2010 and 2013 laid important groundwork by documenting early toxicity profiles and patient-reported quality of life outcomes, helping build the evidence base that influenced clinical adoption of SBRT. His longitudinal research, tracking outcomes over five years, provided the durability data necessary to reassure clinicians and patients alike. Through rigorous multicenter collaboration, Mohideen has helped establish SBRT as a legitimate and well-tolerated standard-of-care option for prostate cancer management.